During HIV/SIV infection, there is widespread programmed cell death in infected and, perhaps more importantly, uninfected cells. Much of this apoptosis is mediated by Fas–Fas ligand (FasL) interactions. Previously we demonstrated in macaques that induction of FasL expression and apoptotic cell death of both CD4+ and CD8+ T cells by SIV is dependent on a functional nef gene. However, the molecular mechanism whereby HIV-1 induces the expression of FasL remained poorly understood. Here we report a direct association of HIV-1 Nef with the ζ chain of the T cell receptor (TCR) complex and the requirement of both proteins for HIV-mediated upregulation of FasL. Expression of FasL through Nef depended upon the integrity of the immunoreceptor tyrosine-based activation motifs (ITAMs) of the TCR ζ chain. Conformation for the importance of ζ for Nef-mediated signaling in T cells came from an independent finding. A single ITAM motif of ζ but not CD3ε was both required and sufficient to promote activation and binding of the Nef-associated kinase (NAK/p62). Our data imply that Nef can form a signaling complex with the TCR, which bypasses the requirement of antigen to initiate T cell activation and subsequently upregulation of FasL expression. Thus, our study may provide critical insights into the molecular mechanism whereby the HIV-1 accessory protein Nef contributes to the pathogenesis of HIV.
Skip Nav Destination
Article navigation
3 May 1999
Article|
May 03 1999
Induction of Fas Ligand Expression by HIV Involves the Interaction of Nef with the T Cell Receptor ζ Chain
Xiao-Ning Xu,
Xiao-Ning Xu
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Bernd Laffert,
Bernd Laffert
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Gavin R. Screaton,
Gavin R. Screaton
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Michael Kraft,
Michael Kraft
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Dietlinde Wolf,
Dietlinde Wolf
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Waldemar Kolanus,
Waldemar Kolanus
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Juthathip Mongkolsapay,
Juthathip Mongkolsapay
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Andrew J. McMichael,
Andrew J. McMichael
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Andreas S. Baur
Andreas S. Baur
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Search for other works by this author on:
Xiao-Ning Xu
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Bernd Laffert
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Gavin R. Screaton
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Michael Kraft
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Dietlinde Wolf
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Waldemar Kolanus
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Juthathip Mongkolsapay
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Andrew J. McMichael
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Andreas S. Baur
From the *Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom; the ‡Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, 91054 Erlangen, Germany; and §Genzentrum, Ludwig-Maximilians-Universität München, 81377 München, Germany
Address correspondence to Andreas S. Baur, Institute of Clinical and Molecular Virology, University of Erlangen/Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany. Phone: 49-9131-852-6784; Fax: 49-9131-852-101; E-mail: [email protected]
X.-N. Xu, B. Laffert, and G.R. Screaton contributed equally to this work.
Received:
February 08 1999
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1999
J Exp Med (1999) 189 (9): 1489–1496.
Article history
Received:
February 08 1999
Citation
Xiao-Ning Xu, Bernd Laffert, Gavin R. Screaton, Michael Kraft, Dietlinde Wolf, Waldemar Kolanus, Juthathip Mongkolsapay, Andrew J. McMichael, Andreas S. Baur; Induction of Fas Ligand Expression by HIV Involves the Interaction of Nef with the T Cell Receptor ζ Chain . J Exp Med 3 May 1999; 189 (9): 1489–1496. doi: https://doi.org/10.1084/jem.189.9.1489
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement